Y-Biologics
Financials
Valuation Metrics
Y-Biologics's Market Cap is ₩1563B. At end of 2025 it was ₩3519B. Ranked #962 of 2,436 in KR market (top 39%), #465 of 1,649 on KOSDAQ (top 28%), #112 of 234 in Pharmaceuticals, Biotechnology & Life Sciences (top 48%) by Market Cap.
Investment Metrics(as of 2026-08-04)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 156.28B KRW | KR#962/2,436 Sec#112/234 |
| Revenue | 2.79B KRW | KR#2,379/2,436 Sec#210/234 |
| Net Income | -44.46B KRW | KR—/2,436 Sec—/234 |
| Total Assets | 53.91B KRW | KR#2,155/2,436 Sec#192/234 |
| Net Assets | 22.42B KRW | KR#2,250/2,436 Sec#210/234 |
| Employees | 60 | KR#1,944/2,436 Sec#170/234 |
| Value | ||
| P/B | 6.97x | KR#2,295/2,436 Sec#194/234 |
| P/S | 56.06x | KR#2,371/2,436 Sec#197/234 |
| FCF Yield | -4.39% | KR—/2,436 Sec—/234 |
| Profitability | ||
| ROE | -198.34% | KR#2,375/2,436 Sec#227/234 |
| ROA | -82.47% | KR#2,378/2,436 Sec#227/234 |
| Op. Margin | -390.67% | KR#2,365/2,436 Sec#201/234 |
| Revenue Growth | -30.77% | KR#2,182/2,436 Sec#199/234 |
| Financial Health | ||
| Debt Ratio | 240.49% | KR#1,956/2,436 Sec#210/234 |
| Total Debt | 15.21B KRW | KR#1,467/2,436 Sec#126/234 |
| FCF | -6.86B KRW | KR#1,590/2,436 Sec#128/234 |
| Cash | 275.9M KRW | KR#2,381/2,436 Sec#229/234 |
| Current Ratio | 16.45x | KR#41/2,436 Sec#14/234 |
| Performance | ||
| 1Y Return | -5.83% | KR#850/2,436 Sec#63/234 |
| 1M Return | -13.37% | KR#1,948/2,436 Sec#194/234 |
| From 52W High | -73.24% | KR#2,239/2,436 Sec#208/234 |
| 1Y MDD | -78.88% | KR#2,271/2,436 Sec#208/234 |
| Trading | ||
| Volume | 104,732 shares | KR#910/2,436 Sec#92/234 |
| Foreign Own. | 8.41% | KR#547/2,436 Sec#50/234 |
| Per Share | ||
| EPS | -2,961 KRW | KR—/2,436 Sec—/234 |
| BPS | 1,477 KRW | KR#2,167/2,436 Sec#189/234 |
Company Info
Y-BIOLOGICS, established in 2007 and listed on KOSDAQ in 2023, focuses on antibody drug research and development. The company leverages its antibody discovery and T-cell bispecific antibody platforms for new drug development, pursuing commercialization through technology transfer and contract research services with global pharmaceutical partners. It has also developed the Multi-AbKine platform for next-generation PD-1 new drugs, employing pH-sensitive antibody mechanism Antibody-Drug Conjugates (ADCs) to specifically target cancer cells.